指南与共识药物不良反应与药物警戒

RIMES清单在药品风险最小化研究中的应用:综述与调查

Use of Reporting Recommendation Intended for Pharmaceutical Risk Minimisation Evaluation Studies (RIMES) Checklist in Risk Minimisation/Mitigation Studies: A Review and Survey.
指南 / 共识 · Drug Saf · 2024-12-17

本研究评估了RIMES清单在2017年12月至2024年1月EUPAS注册的RMM/REMS有效性研究中的使用情况,并通过ISPE调查研究者对清单的认知和使用。纳入44项研究,常见设计为横断面问卷(64%)和回顾性队列(30%),RIMES清单认知度和使用率低,而ENCePP清单使用频繁。结论提示需提高RIMES清单的认知和使用,并协调现有指南。

要点

  • RIMES清单在RMM/REMS有效性研究中认知度和使用率低。
  • ENCePP清单在同类研究中更常用,部分研究者认为其足够。
  • 需提高RIMES清单认知并统一RMM/REMS研究框架。

核心结论

  • 针对RMM/REMS评估设计的RIMES清单认知度和使用率有限,需提升并协调现有指南框架。

研究设计与样本

  • 综述EUPAS注册库中2017年12月1日至2024年1月1日至少在一个欧洲国家进行的RMM/REMS有效性研究,并通过ISPE分发问卷调查研究者认知和使用情况。

主要发现

  • 纳入44项研究,横断面问卷调查研究28项(64%),回顾性队列研究13项(30%)。
  • 肿瘤领域12项(27%),妊娠相关疾病7项(16%)。
  • 多数研究由监管机构要求,通常评估附加的RMM/REMS。
  • RIMES清单认知度和使用率低,ENCePP清单使用频繁。
  • 部分研究者认为ENCePP清单足够,少数提倡RIMES清单。

临床怎么用

  • 在开展RMM/REMS有效性研究时,可参考RIMES清单以提高报告质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Reporting Recommendation Intended for Pharmaceutical Risk Minimisation Evaluation Studies (RIMES) checklist is endorsed by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and is tailored for studies assessing Risk Minimisation Measures and Risk Evaluation and Mitigation Strategy (RMM/REMS) effectiveness; however, its awareness and usage remain unknown. We evaluated the implementation of the RIMES checklist in RMM/REMS effectiveness studies registered in the EUPAS register during 01 December 2017- 01 January 2024. Furthermore, the awareness and utilization of the RIMES checklist among researchers conducting RMM/REMS effectiveness studies was assessed. METHODS: The European Union Post-Authorisation Study (EUPAS) Register was reviewed to identify studies conducted in at least one European country within the specified timeframe. Data were extracted from the online EUPAS registrations, including uploaded study documents. Additionally, a survey was distributed through at International Society of Pharmacoepidemiology (ISPE) to assess awareness and checklist utilisation among researchers. Findings from both the review and the survey were reported descriptively. RESULTS: Among 44 studies included in the review, cross-sectional questionnaire-based surveys (n = 28, 64%), and retrospective cohort studies using secondary data (n = 13, 30%) were frequently used study designs. Oncology (n = 12, 27%) and pregnancy-related conditions (n = 7, 16%) were frequently reported therapeutic areas. Most studies were required by regulators and typically evaluated the additional RMM/REMS. The awareness and usage of the RIMES checklist was low, while the ENCePP checklist was used frequently. Some researchers considered the ENCePP checklist adequate for RMM/REMS studies, while few advocated for the RIMES checklist. CONCLUSION: The awareness and utilisation of the specific RIMES checklist designed for studies evaluating RMM/REMS was limited, indicating a need for improving awareness and utilisation of RIMES and harmonisation of existing guidance and frameworks for RMM/REMS effectiveness studies.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Duckworth SE, Druelles S, Brouwer E, et al. Use of Reporting Recommendation Intended for Pharmaceutical Risk Minimisation Evaluation Studies (RIMES) Checklist in Risk Minimisation/Mitigation Studies: A Review and Survey. Drug Saf. 2024. PMID: 39688763. doi:10.1007/s40264-024-01504-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。